-
In this issue: Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
-
I love this article. It's relevant to our daily practice, but, more importantly, it verbalizes the same issues that both physicians and patients want clarified.
-
-
Add Natazia, an estradiol valerate/dienogest pill, to the list of oral contraceptives approved by the Food and Drug Administration (FDA) and now available to U.S. women.
-
National medical organizations have issued positions on adolescent care will impact your practice. Add the following to the next clinical discussion at your facility:
-
As of September 2010, federal health reform legislation will require all new private health plans to provide coverage of a slate of preventive health services at no cost to patients. Will contraception be included in that coverage? Reproductive health advocates are calling for such measures.
-
When it comes to unplanned pregnancy and sexually transmitted diseases (STDs), young women, adolescents, and the poor often are the most at risk. However, women from all socioeconomic groups face challenges to their sexual and reproductive health.
-
What will it take to stem the incidence of HIV in the United States? According to the Centers for Disease Control and Prevention (CDC), about 56,300 people were newly infected with HIV in 2006, the most recent year for which data are available.
-
Check for use of erectile dysfunction (ED) drugs among older male patients; a new analysis of insurance records of more than 1.4 million U.S. men over 40 found that those who used ED drugs were more likely to have sexually transmitted diseases (STDs) than were non-users.
